Cahit Kural1, Arzu Kaya Kocdogan2, Gulcin Güler Şimşek3, Serpil Oğuztüzün2, Pınar Kaygın2, Irmak Yılmaz2, Tugbag Bayram2, Yusuf Izci4. 1. Department of Neurosurgery, University of Health Sciences and Gulhane Education and Research Hospital, Ankara, Turkey. 2. Department of Biology, Kırıkkale University, Kırıkkale, Turkey. 3. Department of Pathology, University of Health Sciences and Kecioren Education and Research Hospital, Ankara, Turkey. 4. Department of Neurosurgery, University of Health Sciences and Gulhane Education and Research Hospital, Ankara, Turkey, yusufizci@yahoo.com.
Abstract
OBJECTIVE: Intracranial tumors are one of the most frightening and difficult-to-treat tumor types. In addition to surgery, protocols such as chemotherapy and radiotherapy also take place in the treatment. Glutathione S-transferase (GST) and cytochrome P450 (CYP) enzymes are prominent drug-metabolizing enzymes in the human body. The aim of this study is to show the expression of GSTP1, GSTM1, CYP1A1, and CYP1B1 in different types of brain tumors and compare our results with those in the literature. SUBJECTS AND METHODS: The expression of GSTP1, GSTM1, CYP1A1, and CYP1B1 was analyzed using immunostaining in 55 patients with intracranial tumors in 2016-2017. For GST and CYP expression in normal brain tissue, samples of a portion of surrounding normal brain tissue as well as a matched far neighbor of tumor tissue were used. The demographic features of the patients were documented and the expression results compared. RESULTS: The mean age of the patients was 46.72 years; 29 patients were female and 26 were male. Fifty-seven specimens were obtained from 55 patients. Among them, meningioma was diagnosed in 12, metastases in 12, glioblastoma in 9, and pituitary adenoma in 5. The highest GSTP1, GSTM1, and CYP-1A1 expressions were observed in pituitary adenomas. The lowest GSTP1 expression was detected in glioblastomas and the lowest CYP1B1 expression in pituitary adenomas. CONCLUSION: GSTP1 and CYP expression is increased in intracranial tumors. These results should be confirmed with a larger series and different enzyme subtypes.
OBJECTIVE:Intracranial tumors are one of the most frightening and difficult-to-treat tumor types. In addition to surgery, protocols such as chemotherapy and radiotherapy also take place in the treatment. Glutathione S-transferase (GST) and cytochrome P450 (CYP) enzymes are prominent drug-metabolizing enzymes in the human body. The aim of this study is to show the expression of GSTP1, GSTM1, CYP1A1, and CYP1B1 in different types of brain tumors and compare our results with those in the literature. SUBJECTS AND METHODS: The expression of GSTP1, GSTM1, CYP1A1, and CYP1B1 was analyzed using immunostaining in 55 patients with intracranial tumors in 2016-2017. For GST and CYP expression in normal brain tissue, samples of a portion of surrounding normal brain tissue as well as a matched far neighbor of tumor tissue were used. The demographic features of the patients were documented and the expression results compared. RESULTS: The mean age of the patients was 46.72 years; 29 patients were female and 26 were male. Fifty-seven specimens were obtained from 55 patients. Among them, meningioma was diagnosed in 12, metastases in 12, glioblastoma in 9, and pituitary adenoma in 5. The highest GSTP1, GSTM1, and CYP-1A1 expressions were observed in pituitary adenomas. The lowest GSTP1 expression was detected in glioblastomas and the lowest CYP1B1 expression in pituitary adenomas. CONCLUSION:GSTP1 and CYP expression is increased in intracranial tumors. These results should be confirmed with a larger series and different enzyme subtypes.
Authors: Lucienne Juillerat-Jeanneret; Catherine Chapuis Bernasconi; Charlotte Bricod; Solange Gros; Sylviane Trepey; Jean Benhattar; Robert C Janzer Journal: Cancer Invest Date: 2008-07 Impact factor: 2.176
Authors: Mia Hashibe; Paul Brennan; Richard C Strange; Rajani Bhisey; Ingolf Cascorbi; Philip Lazarus; Michael B Oude Ophuis; Simone Benhamou; William D Foulkes; Takahiko Katoh; Christiane Coutelle; Marjorie Romkes; Laura Gaspari; Emanuela Taioli; Paolo Boffetta Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-12 Impact factor: 4.254